1: Torodii D, Holmes JB, Moutzouri P, Nilsson Lill SO, Cordova M, Pinon AC, Grohe K, Wegner S, Putra OD, Norberg S, Welinder A, Schantz S, Emsley L. Crystal structure validation of verinurad via proton-detected ultra-fast MAS NMR and machine learning. Faraday Discuss. 2025 Jan 8;255(0):143-158. doi: 10.1039/d4fd00076e. 2: Dai Y, Lee CH. Transport mechanism and structural pharmacology of human urate transporter URAT1. Cell Res. 2024 Nov;34(11):776-787. doi: 10.1038/s41422-024-01023-1. Epub 2024 Sep 9. 3: Kitzman DW, Voors AA, Mentz RJ, Lewis GD, Perl S, Myte R, Kaguthi G, Sjöström CD, Källgren C, Shah SJ. Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial. JAMA Cardiol. 2024 Oct 1;9(10):892-900. doi: 10.1001/jamacardio.2024.2435.
合成参考文献
参考文献:10.1002/jcph.1119 摘要:Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. The Journal of Clinical Pharma. 2018 May 07;58(9):1214–22. doi: 10.1002/jcph.1119. 摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749